Clinical Monograph • Microbial Consortium Specification

Targeted Probiotic & Astragalus Polysaccharide

4-Strain Targeted Consortium • 50B CFU Potency • Acid-Resistant Matrix

TARGETED SYNBIOTIC CONSORTIUM

ACTIVE MICROBIAL • COMPENDIAL SPECIFICATION
50 BILLION CFU • GASTRIC ACID RESISTANT

Consortium Strains: ST81, BL21, BBi32, LRa66
Prebiotic Scaffold: Astragalus Polysaccharide (≥50%)
Potency Target: 50 Billion Live CFU at Expiry
Delivery Matrix: DRcaps Delayed-Release Hypromellose
Packaging Assay: Alu-Alu Cold Form Moisture Shield

Identification: Whole-genome sequenced verified strains with zero opportunistic antibiotic-resistance plasmids.

Ingredients & Formulation

Four human-origin probiotic strains (ST81, BL21, BBi32, LRa66) embedded in a standardized Astragalus membranaceus polysaccharide matrix. Formulated to withstand human stomach acid (pH 1.5–2.0) for targeted release in the distal ileum and colon.

Research Summary

Documented across 9 published clinical and in vitro trials. Meta-review validates enhanced short-chain fatty acid (butyrate) synthesis, preservation of tight-junction Claudin-1 proteins, and modulation of mucosal secretory IgA.

Dosage & Clinical Administration

Standard maintenance dose: 1 delayed-release capsule daily with morning water. Therapeutic gut barrier re-seeding protocol: 2 capsules daily for 14 days under physician oversight.

Clinical Precaution: Avoid concomitant oral antibiotic dosing within a 2-hour window.

DNA SEQUENCED VEGAN HPMC 50B CFU LIVE SOLVENT FREE

Educational compendium analysis. Not prescriptive medical advice.

Audit Methodology → Download PDF Monograph (PDF) ↓